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Abstract. Background: Secondary hyperparathyroidism is a frequent complication
of chronic kidney disease (CKD). The goal of
treatment is to achieve circulating levels of
parathyroid hormone (PTH) associated without oversuppression of bone turnover. This is
commonly achieved by treatment with vitamin D analogs. Doses of vitamin D compounds are usually monitored by measurement of circulating levels of PTH. Study design: To prospectively assess the effects on
bone histology of two different protocols for
dosing vitamin D. Setting and participants:
African-American patients from the same
geographic area, managed by the same team
of physicians in three dialysis clinics were
studied. Patients were treated with vitamin D
for 3 years and underwent bone biopsies for
assessment of bone turnover. Dosing of vitamin D during the 3 years prior to the biopsy
was done following two different guidelines.
One group was treated following K/DOQI
guidelines adapted to the bio-intact PTH assay (Protocol A), the other group was managed (Protocol B) following K/DOQI guidelines for intact PTH and/or the ratio of
PTH-(1-84)/N-terminally truncated fragments (PTH ratio). Predictor: Levels of circulating PTH and/or PTH ratio. Outcome: Prevalence of low bone turnover. Measurements:
Qualitative and quantitative assessment of
bone histology after tetracycline labeling. Results: 7 out of 22 patients managed following
Protocol A were found to have low bone turnover (32%) by bone histology. None of the 21
patients managed by Protocol B for guidance
of vitamin D therapy, had low bone turnover.
Limitations: Lack of bone biopsy at the beginning of study. Conclusions: This report indicates that the additional information pro-

vided by the PTH ratio represents a distinct
advantage in avoiding low bone turnover
over the use of a single PTH assay to guide vitamin D dosing in African-American patients
with CKD Stage 5 on dialysis.

Introduction
Secondary hyperparathyroidism occurs
early in the development of chronic kidney
disease (CKD) [Gutierrez et al. 2008, Lehmann et al. 2008, Malluche et al. 1976] and
results in bone disease characterized by various degrees of increased bone turnover. The
most commonly employed treatment of secondary hyperparathyroid bone disease is vitamin D therapy, which has been shown to
have positive effects on renal osteodystrophy
[Goldstein et al. 1980, González 2008, Indridason and Quarles 2000, Malluche et al. 1980,
Mochizuki et al. 2007, Staniforth et al. 2005]
and patient survival [Kalantar-Zadeh et al.
2006, Kovesdy et al. 2008, Melamed et al.
2006, Shoji et al. 2004, Teng et al. 2003,
2005, Tentori et al. 2006]. However, overdosing of vitamin D therapy carries the undesirable risk to induce over-suppression of bone
turnover [Baker et al. 1989, Goodman et al.
1994, Kazama et al. 2005, Salusky et al.
1998]. It is therefore of utmost importance to
provide a carefully guided course of vitamin
D treatment to CKD-5 patients. The intact
parathyroid hormone assay (iPTH) is widely
used as a surrogate for bone biopsy in the di-
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agnosis of renal osteodystrophy [Andress
2005, Goodman 2007, Hernandez et al. 2005,
Salusky et al. 2003]. However, studies have
shown that the iPTH assay in fact measures
both PTH-(1-84) and N-terminally truncated
fragments which have opposing biological
actions. More recently, the Bio-IntactTM PTH
(bio-PTH) assay was introduced, which measures only PTH-(1-84) and has been used routinely and interpreted as approximately half
the value of the intact PTH assay value
[Salusky et al. 2003]. Subtraction of PTH(1-84) from the intact PTH results allows to
calculate the N-terminally truncated fragments. It was proposed that the ratio between
PTH-(1-84) and the fragments (PTH ratio) is
a better indicator of bone turnover than
PTH-(1-84) or intact PTH [Monier-Faugere
et al. 2001].
African-American patients are of particular interest with respect to vitamin D therapy
because of the known difference in blood levels of PTH between African-Americans and
white patients [Bell et al. 2001, Fuleihan et al.
1994]. It has been demonstrated that the average level of iPTH is higher in African-American patients with pre-dialysis CKD [Gutierrez
et al. 2008] and CKD-5 on dialysis [Gupta et
al. 2000, Wolf et al. 2007] compared to their
white counterpart. African-American CKD-5
patients constitute 29% of the total CKD population in the US and the incidence of CKD-5
among African-Americans is nearly 3 times
that of white CKD-5 patients [US Renal Data
System 2006]. Current K/DOQI guidelines

Table 1. Demographic characteristics at time of bone biopsy in 43 CKD Stage 5
patients following two different protocols for vitamin D dosing.

Age (years)
Sex (m/f)
Dialysis vintage (months)
Diabetics (%)

Protocol A
(n = 22)

Protocol B
(n = 21)

p values

57.0 ± 2.26

50.3 ± 2.60

0.074

13/9

9/12

0.366

33 ± 6

37 ± 5

0.826

31.8

33.3

1.000

Phosphate binders

0.819

Sevelamer hydrochloride

14

15

Calcium acetate

6

3

Sevelamer + calcium

2

0

No phosphate binder

0

3

[K/DOQI Clinical Practice Guidelines 2003]
do not discern between African-Americans
and white patients. Studies using bone biopsies have shown that the average iPTH value
for African-American CKD-5 patients with
adynamic bone disease is the same as in white
patients with high bone turnover disease
[Sawaya et al. 2003]. This calls for an alternative guideline for African-American CKD-5
patients to the standard guideline of an iPTH
range of 150 – 300 pg/ml in order to prevent
oversuppression of parathyroid glands. This
issue has great clinical relevance since
adynamic bone disease, which is on the rise
[Malluche et al. 2004, Malluche and MonierFaugere 1992, Monier-Faugere and Malluche
1996], is associated with arterial calcification
in CKD-5 patients [Adragao et al. 2006,
Blacher et al. 2001, London et al. 2004] and
increased morbidity/mortality [Block et al.
2004, 2007, Stevens et al. 2004].
The study tested the hypothesis that using
the PTH ratio, which informs on the relative
quantity of active PTH-(1-84) and antagonist
PTH-(7-84), in addition to intact PTH instead
of PTH alone following the K/DOQI for
guidance of vitamin D dosing will result in
lower prevalence of adynamic bone disease.

Patients and methods
Study design
The study was designed as a prospective
cross-sectional study. Effects of implementation of two different protocols for dosing active vitamin D for PTH management and resulting bone histology changes after 3 years
were studied. The study was approved by the
Henry Ford’s IRB and the study was conducted in adherence with the Declaration of
Helsinki.

Patients
Patients were recruited from three dialysis
clinics of the same geographic area. Patients
were seen by the same team of physicians following the same standard management policies with exception of monitoring of vitamin
D therapy. Details on patient demographics
who underwent bone biopsy are shown in
Table 1.
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Table 2.

Vitamin D dosing protocols.

Dosing

Protocol A

Protocol B

Reduce dose if:

bio-PTH < 75 pg/ml

iPTH < 150 pg/ml OR PTH ratio < 1.4

Maintain dose if:

bio-PTH = 75 – 150 pg/ml

iPTH = 150 – 300 pg/ml AND PTH ratio > 1.4

Increase dose if:

bio-PTH > 150 pg/ml

iPTH > 300 pg/ml AND PTH ratio > 1.4

Note: to convert blood PTH from pg/ml to ng/l, multiply by 1.

Inclusion and exclusion criteria
Inclusion criteria were chronic maintenance hemodialysis patients of African-American ethnicity, ages 18 – 80 years on vitamin
D therapy. Exclusion criteria were patients
with iPTH less than 100 pg/ml, during the
past 6 months, treatment with cinacalcet
HCL, steroids or other immunosuppressive
agents or change in dose of vitamin D of more
than 50%. In addition, patients were excluded
who had previously undergone a parathyroidectomy or were known to have malignancy.
Patients who qualified and agreed to participate in the study signed informed consent
form in the presence of a witness.

Vitamin D dosing
Vitamin D dosing was done following two
different protocols (Protocols A and B) as
shown in Table 2. Vitamin D dosing was reduced if bio-PTH levels were less than 75
pg/ml (Protocol A) or iPTH levels were less
than 150 pg/ml or PTH ratio was less than 1.4
(Protocol B). Vitamin D doses were maintained if bio-PTH was between 75 and 150
pg/ml (Protocol A) or iPTH was between 150
and 300 pg/ml and PTH ratio > 1.4 (Protocol
B). Increase in vitamin D dosing was instituted if bio-PTHI was > 150 pg/ml (Protocol
A) or iPTH > 300 pg/ml and PTH ratio > 1.4.
The threshold levels of bio-PTH were calculated based on the K/DOQI guidelines and the
fact that it was shown that iPTH levels are approximately 50% higher than levels measured
by bio-PTH [Salusky et al. 2003]. In addition,
dosages of vitamin D were adjusted based on
monitoring of serum calcium, phosphorus
and calcium × phosphate product levels following K/DOQI guidelines. Paricalcitol was

the vitamin D analog used in all patients with
the exception of 1 patient in Protocol A and
2 patients in Protocol B patients who were
treated with calcitriol.

Biochemical and PTH assays
Blood samples were obtained on the day
of bone biopsy in the fasting state. Serum calcium and phosphorus were measured by routine laboratory techniques. Serum bone-specific alkaline phosphatase levels were
measured using an immunocapture enzyme
activity assay (Metra BSAP EIA kit). The
normal range of the assay is 11.6 – 29.6 U/l
for premenopausal women; 14.2 – 42.7 U/l
for postmenopausal women; and 15.0 – 41.3
U/l for men. The intra- and inter-assay coefficients of variation are < 6% and < 8%, respectively.
For PTH measurements, blood was collected in ethylenediaminetetraacetic acid
(EDTA), evacuated collection tubes, inverted
gently 5 times and centrifuged at 500 × g for
10 – 15 minutes. All samples were processed
into plasma within 60 minutes of blood collection. Plasma was then aliquoted into
cryovials and stored at –20 ºC until the time of
the PTH assay(s). PTH was measured according to the manufacturer’s instructions using
either the Bio-IntactTM PTH Assay (Nichols
Institute Diagnostics, San Clemente, CA,
USA) or the Total Intact PTHTM Assay
(tPTH) and the 1-84 Whole PTH (CAPTM Assay values (Scantibodies Laboratory, Santee,
CA, USA). The N-terminally truncated PTH
fragments were calculated by subtracting
PTH-(1-84) from the total PTH. The PTH ratio was calculated by dividing PTH-(1-84) by
the N-terminally truncated PTH fragments.
For Bio-Intact PTH assay the intra- and
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Table 3. Biochemical and hormonal results at time of bone biopsy in 43 CKD Stage 5 patients following
two different protocols for vitamin D dosing.

Serum calcium (mg/dl)

Protocol A
(n = 22)

Protocol B
(n = 21)

p values

8.86 ± 0.09

9.0 ± 0.14

0.481

Serum phosphorus (mg/dl)

4.94 ± 0.26

5.56 ± 2.51

0.123

Serum calcium x phosphorus product

43.9 ± 2.49

50.2 ± 2.51

0.146

Serum bone-specific alkaline phosphatase (U/l)

25.8 ± 2.70

45.3 ± 3.94*

0.001

Plasma PTH levels (pg/ml)
Total PTH
Whole PTH
PTH ratio
Bio-PTH

612 ± 36.7

Dose of vitamin D/dialysis session (µg equivalent)

5.77 ± 0.79

732 ± 101
424 ± 57
1.66 ± 0.19

3.05 ± 0.39*

0.006

*Significantly different from Protocol A, p < 0.01; doses of vitamin D averaged over the 6 months prior to
bone biopsy.
Note: to convert serum calcium from mg/dl to mmol/l, multiply by 0.2495; serum phosphorus from mg/dl to
mmol/l, multiply by 0.3229; plasma PTH levels from pg/ml = ng/l.

interassay coefficients of variation are 2.2%
and 7.6%, respectively, and the normal range
is 6 – 40 pg/ml. Intraassay coefficients of
variation for the tPTH and CAP assays are
3.77% and 4.0%, respectively. The interassay
coefficients of variation are 5.18% and
5.45%, respectively. Normal ranges are 14 –
66 pg/ml and 5 – 39 pg/ml, respectively.

Bone biopsy and mineralized
bone histology
Bone biopsies were performed as previously described [Malluche and Monier-Faugere
1994] after 3 years of vitamin D management
following the two different protocols. Briefly,
for bone labeling, patients received tetracycline hydrochloride at a dose of 250 mg
orally, 3 times a day for 3 days, 20 days before
bone biopsy. No tetracycline hydrochloride
was administered for the following 11 days. A
second administration of oral tetracycline hydrochloride (250 mg 3×/d) or demeclocycline
hydrochloride (Declomycin®, Lederle,
Wayne, NJ, USA) (300 mg 2×/d) was administered for the next 3 days. Bone biopsies
were performed 4 days after the last dose of
tetracycline. Phosphate binders and other antacids were not given on days of tetracycline
administration.

Bone samples were processed without removal of the mineral as previously described
[Malluche and Faugere 1986]. Sections were
stained with the modified Masson-Goldner
trichrome stain [Goldner 1938], the aurin-tricarboxylic acid stain [Lillie and Fullmer
1976], and solochrome azurin [Denton et al.
1984]. Unstained sections were prepared for
phase contrast and fluorescent light microscopy. Presence of adynamic bone disease was
established by quantitative assessment of activation frequency. Adynamic bone disease
was diagnosed when activation frequency was
below 0.49 y–1 or bone formation rate/bone
surface below 1.8 mm3/cm2/y and osteoid
thickness < 20 mm.

Statistical methods
Results are expressed as means ± SEM.
Comparison of categorical variables between
the two protocols was made using the Fisher’s
exact test. Comparison between continuous
variables was made using the Mann-Whitney
U-test. Correlation coefficients between
histomorphometric parameters of bone and
PTH results were computed using the Spearman test. Multivariate associations were assessed using logistic regression analysis to
determine the effects of protocol or vitamin D
dose on low bone turnover, adjusted for age,
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Table 4.
ing.

Static and dynamic histomorphometric of bone in 43 CKD Stage 5 patients following two different protocols for vitamin D dos-

Histomorphometric parameters of bone

Protocol A
(n = 22)

Protocol B
(n = 21)

Normal values

Bone volume/tissue volume (%)

24.2 ± 1.76

26.2 ± 2.00

16.8 – 22.9

Trabecular thickness (mm)

124 ± 6

133 ± 8

99 – 142

Trabecular separation (mm)

429 ± 37

396 ± 32

280 – 658

Osteoid volume/bone volume (%)

4.57 ± 0.69

9.49 ± 1.00**

0.57 – 6.0

Osteoid surface/bone surface (%)

25.1 ± 2.52

40.8 ± 2.59**

3.45 – 37.9

Woven osteoid surface/osteoid surface (%)

3.54 ± 1.36

10.4 ± 2.46**

0

Osteoid thickness (mm)

10.5 ± 0.63

14.3 ± 0.87**

4 – 20

Number of osteoblasts/bone perimeter (#/100 mm)

184 ± 44.7

593 ± 118**

1 – 200

Erosion surface/bone surface (%)

6.85 ± 1.33

10.3 ± 1.28**

0.1 – 5.69

Erosion depth (mm)

18.0 ± 1.60

25.8 ± 2.38*

4.3 – 7.3

Number of osteoclasts/bone perimeter (#/100 mm)

71.9 ± 14.5

105 ± 14.4**

0.1 – 53

Fibrosis surface/bone surface (%)

3.65 ± 1.00

11.5 ± 3.15**

0

Mineral apposition rate (mm/d)a

1.00 ± 0.10

1.26 ± 0.09*

0.36 – 0.63

Mineralizing surface/bone surface (%)a

8.54 ± 1.42

12.6 ± 1.16*

4 – 12

Bone formation rate/bone surface (mm3/cm2/yr)a

3.84 ± 0.59

5.79 ± 0.68*

1.80 – 3.08

Mineralization lag time (d)a

44.5 ± 7.38

56.3 ± 9.35

< 50

Activation frequency (y–1)a

0.81 ± 0.14

1.06 ± 0.10*

0.49 – 0.72

an = 16 for Protocol A and n = 18 for Protocol B. *Significantly different from Protocol A, p < 0.05. **Significantly different from Protocol A,

p < 0.01.

duration on dialysis, and diabetes. Computations and analyses were performed using
SPSS 7.5 software package for Windows
(SPSS, Inc., Chicago, IL, USA).

Results
43 patients fulfiled the selection criteria
and agreed to participate in the study. The patients from the two protocols who underwent
bone biopsies were comparable with respect
to age, sex, dialysis vintage and diabetic status (Table 1). Also there were no significant
differences in serum calcium and phosphorus
levels and calcium × phosphate products at
time of biopsy between the two protocols (Table 3). Using the PTH ratio as a guide for therapy (Protocol B) resulted in an overall lesser
vitamin D dose administered, averaged over
the 6 months prior to biopsy (Table 3). In Protocol A, 7/22 patients (32%) were found to
have adynamic bone disease. In contrast, in
Protocol B, where therapy was guided by the

PTH ratio in combination with iPTH, no
adynamic bone disease was found. The difference in prevalence of adynamic bone disease between the two protocols was statistically significant (p < 0.01). Parameters of
bone structure were not different between the
two protocols (Table 4), however, static and
dynamic parameters of bone turnover were
significantly higher in patients treated with
vitamin D following Protocol B than in patients of Protocol A. There were no correlations between any of the PTH results and
static and dynamic parameters of bone turnover (r ranging from 0.05 – 0.36). Moreover,
there was no difference in PTH levels when
patients were classified as having low, normal
or high bone turnover in Protocol A or between normal and high bone turnover in Protocol B (Figure 1). Comparison between patients with adynamic bone disease and
patients with normal or high bone turnover
followed by Protocols A and B did not show
differences in prevalence of factors known to
be associated with adynamic bone disease.

Fehmi, Osman, Bhat et al.

Figure 1. Plasma PTH concentrations at time of
bone biopsy in patients with low, normal, or high
bone turnover following Protocols A and B for vitamin D dosing. Protocol A used bio-PTH levels for
guidance of vitamin D therapy. Protocol B used
iPTH and/or PTH ratio for guidance of vitamin D
therapy.

These include age, sex, diabetes, dialysis vintage, phosphate binders, and serum calcium
and phosphorus levels. When all patients
were pooled, logistic regression showed that
low bone turnover was predicted by protocol,
and not vitamin D dose.

Discussion
The present study shows that following
the PTH ratio together with intact PTH is superior to following results of one PTH assay
alone for monitoring vitamin D dosing in preventing development of adynamic bone
disease.
For African-American hemodialysis patients, who make up 29% of the total dialysis
population [US Renal Data System 2006], the
average intact parathyroid hormone (iPTH)
values for adynamic bone disease have been
demonstrated to be 3 times higher than iPTH
values for white patients with adynamic bone
disease or equivalent to the iPTH values for
high bone turnover disease for white hemodialysis patients [Sawaya et al. 2003]. It is,
therefore, difficult to apply the K/DOQIbased treatment guidelines for AfricanAmerican CKD-5 patients and avoid inappropriate dosing of vitamin D. The K/DOQI
guidelines were based on results from patient
studies in which information on race was not
available [Cannella et al. 1994, Carmen
Sanchez et al. 2000, Dressler et al. 1995,
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Frazeo et al. 2000, Fukagawa et al. 1994,
Llach et al. 1995, Quarles et al. 1992, Solal et
al. 1991, Sprague and Moe 1992]. It was
shown that although African-Americans exhibited higher overall PTH values compared
to white hemodialysis patients, the PTH(1-84)/PTH-(7-84) ratio was lower, indicating a higher proportion of PTH-(7-84) in the
African-American versus white CKD-5 patient [Fehmi et al. 2006]. Since PTH-(7-84)
has been shown to antagonize the effects of
PTH-(1-84) on calcium and bone turnover
[Langub et al. 2003, Nguyen-Yamamoto et al.
2001, Slatopolsky et al. 2000], this might explain, at least in part, why with higher levels
of circulating PTH, bone does not show a
commensurate increase in bone turnover. The
present study confirms a previous report that
showed lack of correlation between PTH levels and static and dynamic histomorphometric parameters of bone turnover in African-American CKD-5 patients [Sawaya et al.
2003]. This explains the lack of differences in
PTH levels between patients with various levels of bone turnover. Moreover, vitamin D
treatment may have had a confounding effect
on bone turnover and could have overridden
the effects of PTH in the studied AfricanAmerican patients [Malluche et al. 1986].
In Protocol A, a higher amount of vitamin
D analog was used. The mean dose of vitamin
D administered per hemodialysis session (averaged over the 6 months prior to bone biopsy) in Protocol B was 3.5 ± 0.39 mg,
whereas, in Protocol A 5.77 ± 0.79 mg were
given. However, in the multivariate analysis,
the average vitamin D dose was not an independent factor in the prediction of adynamic
bone disease. Serum levels of 25 or 1,25 vitamin D were not measured but it can be assumed that circulating vitamin D concentrations were larger in Protocol A. It has been
shown that excessive vitamin D administration may lead to oversuppression of bone
turnover [Baker et al. 1989, Goodman et al.
1994, Malluche and Monier-Faugere 1992].
The current study cannot definitively establish a cause and effect relationship between
vitamin D and adynamic bone disease, but no
other factor could be identified for the
adynamic state.
A previous study [London et al. 2004] has
helped to clarify the specific morbid effects
associated with excessive lowering of para-
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thyroid activity. Using bone biopsies and arterial calcification scoring, it was shown that
adynamic bone disease is associated with arterial calcification in CKD-5 patients, as opposed to hyperparathyroidism. This was a
critical finding in light of a separate study
conducted in 2001 [Blacher et al. 2001] that
disclosed a correlation between arterial calcification and CKD-5 patient mortality. The
high incidence of soft tissue calcification associated with chronic dialysis was reported
more than 30 years ago [Ritz et al. 1974] and
has since been confirmed by other studies
[Goodman et al. 2000]. Autopsy results revealed that dialysis patients exhibit twice the
amount of the soft tissue calcification of nondialysis patients [Kuzela et al. 1977]. It was
also shown that in the first year of dialysis,
there is a correlation between higher PTH ratios and survival [Tamez et al. 2007].
One limitation of the study is that no bone
biopsies were performed before introducing
the two different vitamin D dosing protocols.
However, the finding of absence of adynamic
bone disease in vitamin D-treated AfricanAmerican CKD-5 patients who are known to
have generally lower bone turnover than their
white counterpart has never been observed
before. Prevalence of adynamic bone disease
in unselected dialysis population was reported
to be approximately 40% [Ferreira et al. 2008,
Malluche et al. 2004, Pei et al. 1995].
This report indicates that the additional
information provided by the PTH ratio represents a distinct advantage in avoiding low
bone turnover over the use of a single PTH assay to guide vitamin D dosing in AfricanAmerican patients with CKD Stage 5 on
dialysis.
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